Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00465907
Status:
TERMINATED
Last Update Posted:
2019-02-11
First Post:
2007-04-23
Brief Title:
Study of Weekly Paclitaxel Carboplatin and Irinotecan to Treat Lung Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Phase II Study of Weekly Paclitaxel Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Pleural Effusion
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the efficacy and toxicity of the weekly combination chemotherapy of Paclitaxel Carboplatin and Irinotecan in Stage IIIb and IV NSCLC with malignant pleural effusion
Detailed Description:
Lung cancer is the leading cancer death in many countries of the world including Singapore Non-small cell lung cancer NSCLC consists of 80-85 of lung cancers and is a major health problem The main etiology of lung cancer is well recognized and established to be cigarette smoking which accounts for up to 80 of the cases in the western countries Due to success of anti-smoking campaign we anticipate to see less smoking related lung cancer and more non-smoking related lung cancer which is rising rapidly For eg currently in Singapore smoking only accounts for 50-60 of all lung cancers this is particularly true in female patients as smoking occured in 30-40 of female lung cancer patients only
It is unclear if there is any significant difference in the fundamental biology between smoking and non-smoking related lung cancers particularly in areas of natural course of disease genetic changes of tumor cells clinical presentation response to treatment or survival These are potential aspects for further investigation
It is unclear if there is any significant difference in the fundamental biology between smoking and non-smoking related lung cancers particularly in areas of natural course of disease genetic changes of tumor cells clinical presentation response to treatment or survival These are potential aspects for further investigation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NA_00037282 | OTHER | JHM IRB | None |